COTA Inc., a leader in real-world data and analytics for oncology, announces a new partnership with leading precision oncology company Guardant Health Inc. that will allow biopharmaceutical researchers to access the combined resources of COTA’s research-grade electronic health record (EHR) data from academic and community care centers and Guardant’s clinicogenomic testing data to accelerate the development of new cancer therapies.
Using the extensive dataset and AI analytics the collaboration provides, research scientists can more easily understand and further validate correlations between molecular biomarkers, treatment decisions and clinical outcomes. They can also gain greater insights into existing data research and gather the comprehensive data—including critical longitudinal serial testing information—needed to optimize drug development and accelerate programs that treat cancer across diverse patient populations.
“Clinicogenomic data empowers research scientists to test hypotheses by studying patient genomic profiles and real-world outcomes to guide the development of targeted therapies that can be used to personalize treatment for each cancer patient,” said Dr. C.K. Wang, chief medical officer at COTA. “Connecting Guardant’s data to COTA’s in-depth, real-world oncology data assets will also allow researchers to anticipate treatment responses and accelerate drug development for existing and new population segments.”
Also Read: Radiology Partners and RADPAIR Forge Strategic Partnership
The drug development process can take up to fifteen years, with 97% of cancer clinical trials failing. As a result, life sciences organizations are investing heavily in multi-modal data sets like clinicogenomics. By gaining insights into how different patient populations respond to therapies in real-world settings, drug developers can facilitate biomarker discovery, refine clinical trials, accelerate approvals, and bring targeted, life-saving treatments to market more quickly.
“The real-world data partnership with COTA marks another milestone in our mission to conquer cancer with data,” said Craig Eagle, MD, Guardant Health chief medical officer. “Giving biopharmaceutical researchers the ability to connect detailed information about tumor biology and therapy response with real-world patient outcome data will expedite the discovery of new biomarker-based therapies for patients and make the drug development process more economical as well.”
Guardant’s extensive real-world longitudinal serial testing datasets span all stages of the disease, from initial tumor profiling for therapy selection to recurrence and therapy response monitoring, while COTA’s highly curated data tracks a patient’s complete cancer care journey, drawing from both academic and community care center settings. This new collaboration with Guardant deepens COTA’s data by expanding its breadth into solid tumors, particularly lung, breast, and colorectal cancers, creating a broader, more diverse data set with considerable patient overlap for enhanced clinical insights.
SOURCE: Businesswire
